Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.39 |
| ▸ | MMP12 | P39900 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970478 | 1.00 | MMP13 (0.39) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL2967822 | 0.80 | MMP13 (0.41) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL75900 | 0.80 | MMP13 (0.41) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL74108 | 0.80 | MMP13 (0.41) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL8342071 | 0.74 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL13209012 | 0.72 | LMNA (0.48) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL13209009 | 0.70 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL15427305 | 0.70 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL1132700 | 0.70 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL1363544 | 0.70 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772403-B2 | Process to prepare sulfonyl chloride derivatives | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1999115-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007106021-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | SLC5A1, GCG, IAPP | MMP13 4718/4885MMP12 4848/4885SMN1; SMN2 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.